JP2020200332A5 - - Google Patents

Download PDF

Info

Publication number
JP2020200332A5
JP2020200332A5 JP2020140379A JP2020140379A JP2020200332A5 JP 2020200332 A5 JP2020200332 A5 JP 2020200332A5 JP 2020140379 A JP2020140379 A JP 2020140379A JP 2020140379 A JP2020140379 A JP 2020140379A JP 2020200332 A5 JP2020200332 A5 JP 2020200332A5
Authority
JP
Japan
Prior art keywords
seq
antigen
group
binding fragment
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020140379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020200332A (ja
JP7079298B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020200332A publication Critical patent/JP2020200332A/ja
Publication of JP2020200332A5 publication Critical patent/JP2020200332A5/ja
Application granted granted Critical
Publication of JP7079298B2 publication Critical patent/JP7079298B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020140379A 2011-10-14 2020-08-21 Ｗｎｔ経路関連疾患のための抗体および方法 Active JP7079298B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547209P 2011-10-14 2011-10-14
US61/547,209 2011-10-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017192565A Division JP2018016634A (ja) 2011-10-14 2017-10-02 Ｗｎｔ経路関連疾患のための抗体および方法

Publications (3)

Publication Number Publication Date
JP2020200332A JP2020200332A (ja) 2020-12-17
JP2020200332A5 true JP2020200332A5 (https=) 2021-02-04
JP7079298B2 JP7079298B2 (ja) 2022-06-01

Family

ID=47278355

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014535221A Withdrawn JP2014530816A (ja) 2011-10-14 2012-10-12 Ｗｎｔ経路関連疾患のための抗体および方法
JP2017192565A Withdrawn JP2018016634A (ja) 2011-10-14 2017-10-02 Ｗｎｔ経路関連疾患のための抗体および方法
JP2020140379A Active JP7079298B2 (ja) 2011-10-14 2020-08-21 Ｗｎｔ経路関連疾患のための抗体および方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014535221A Withdrawn JP2014530816A (ja) 2011-10-14 2012-10-12 Ｗｎｔ経路関連疾患のための抗体および方法
JP2017192565A Withdrawn JP2018016634A (ja) 2011-10-14 2017-10-02 Ｗｎｔ経路関連疾患のための抗体および方法

Country Status (6)

Country Link
US (2) US9296826B2 (https=)
EP (2) EP2766033B1 (https=)
JP (3) JP2014530816A (https=)
CN (2) CN104080471B (https=)
ES (1) ES2769786T3 (https=)
WO (1) WO2013054307A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2173379B2 (en) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP6185463B2 (ja) 2011-07-15 2017-08-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ結合剤およびその使用法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
ES2797533T3 (es) 2012-02-28 2020-12-02 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9181333B2 (en) 2012-07-13 2015-11-10 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
BR112016008477A2 (pt) 2013-10-18 2017-10-03 Genentech Inc Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
CN106714831A (zh) * 2014-04-21 2017-05-24 艾伯维施特姆森特克斯有限责任公司 新的抗‑rnf43抗体和使用方法
IL282156B (en) * 2014-07-29 2022-07-01 Shenzhen Hightide Biopharmaceutical Ltd Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
US11000521B2 (en) 2015-08-03 2021-05-11 Institut Pasteur Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
EP3865511A1 (en) 2016-04-14 2021-08-18 F. Hoffmann-La Roche AG Anti-rspo3 antibodies and methods of use
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
CN117946267A (zh) 2017-12-19 2024-04-30 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
CA3104868A1 (en) * 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
WO2020132356A1 (en) * 2018-12-19 2020-06-25 Surrozen, Inc. Antigen binding formats for receptor complexes
AU2019416324A1 (en) * 2018-12-27 2021-07-22 H. Lee Moffitt Cancer Center And Research Institute Inc. Bispecific antibody for membrane clearance of target receptors
CA3141632A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
MX2022005241A (es) * 2019-11-01 2022-07-27 Univ California Degradacion de proteinas de superficie usando agente de union biespecifico.
WO2021092199A1 (en) * 2019-11-08 2021-05-14 Kansas State University Research Foundation Isolation, preservation, and expansion of canine umbilical cord mesenchymal stromal cells
US20230241161A1 (en) * 2020-01-10 2023-08-03 Inserm (Institutnationaldelasanteetdelarecherchemedicale) Rspo1 proteins and their use
AU2021232625A1 (en) * 2020-03-05 2022-09-29 Umc Utrecht Holding B.V. Membrane ubiquitin ligases to target protein degradation
JP2023532431A (ja) * 2020-06-18 2023-07-28 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 標的－ｅ３リガーゼの有効な組合せのスクリーニング法
CN111920951B (zh) * 2020-07-17 2022-12-06 上海交通大学医学院附属瑞金医院 Znrf3/rnf43在制备调节能量代谢药物中的应用
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
WO2022169872A1 (en) * 2021-02-03 2022-08-11 Genentech, Inc. Multispecific binding protein degrader platform and methods of use

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
EP1513934B1 (en) 2002-06-06 2011-03-02 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
WO2004032838A2 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
RU2007104925A (ru) 2004-07-09 2008-08-20 Те Риджентс Оф Те Юниверсити Оф Калифорния (Us) СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ АГЕНТОВ, КОТОРЫЕ ИНГИБИРУЮТ СИГНАЛЬНЫЙ ПУТЬ Wnt16
WO2007027509A2 (en) 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
US20090047276A1 (en) * 2007-05-15 2009-02-19 University Of Washington Methods for increasing cell or tissue regeneration in a vertebrate subject
EP2173379B2 (en) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
BRPI0820327A2 (pt) 2007-11-02 2020-10-06 Novartis Ag moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
WO2010016766A2 (en) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
WO2011004379A1 (en) 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
ES2797533T3 (es) 2012-02-28 2020-12-02 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43

Similar Documents

Publication Publication Date Title
JP2020200332A5 (https=)
JP6206972B2 (ja) グルカゴン様ペプチド−２組成物およびその作製法および使用法
CN101541957B (zh) 利尿钠多肽
JP6352911B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
ES3056164T3 (en) Compositions, formulations, and interleukin production and purification
JP2019510739A5 (https=)
Gulati et al. A Novel Neuroregenerative Approach Using ET B Receptor Agonist, IRL-1620, to Treat CNS Disorders.
JP2013517783A5 (https=)
JP2004504032A5 (https=)
JP2009213477A5 (https=)
WO2005025616A1 (ja) 抗体の用途
JP2017531613A5 (https=)
Al Musaimi FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond
JP2006506942A5 (https=)
JP2017221201A5 (https=)
JP2023528204A5 (https=)
JP2018517409A (ja) セリアックスプルー病を治療するための組成物および方法
US10905750B2 (en) GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
JP2022516660A5 (https=)
JPWO2017150536A1 (ja) ペプチド
JP2025510591A5 (https=)
JP2022049715A (ja) インスリン分泌促進ペプチド
JP4570402B2 (ja) 中枢機能改善剤
JP2005538041A5 (https=)
JP3723838B2 (ja) 新規な抗脱毛ペプチド